Barinthus Biotherapeutics Initiates First-in-Human Trial of VTP-1000 for Celiac Disease
Barinthus Biotherapeutics is conducting a first-in-human trial to evaluate the safety and tolerability of VTP-1000 in adults with celiac disease.
Therapeutic Area
Therapeutic area intelligence for Celiac Disease with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.